Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
Mark T. Drayson(Institute of Immunology), Janet Dunn(National Health Service), Claire Hulme(University of Leeds), Kamaraj Karunanithi(University Hospitals of North Midlands NHS Trust), Irene M. Monahan(St George's, University of London), Peter M. Hawkey(University of Birmingham), Beth Harrison(Brigham and Women's Hospital), Gavin Campbell(East Suffolk and North Essex NHS Foundation Trust), Kerry Raynes(University of Warwick), Bryony Dawkins(University of Leeds), Edward Belsham(Portsmouth Hospitals NHS Trust), Helen Higgins(University of Warwick), Helen Dignum(Portsmouth Hospitals NHS Trust), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Anand Lokare(University Hospitals Coventry and Warwickshire NHS Trust), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Gulnaz Iqbal(University of Warwick), David Meads(University of Leeds), Stella Bowcock(King's College Hospital), Eric Low(Myeloma UK), Jill Wood(University of Warwick), Anna C. Phillips(University of Stirling), Michael R. Hamblin(University of Johannesburg), Jeff Neilson(Russells Hall Hospital), Tim Planche(Leeds Teaching Hospitals NHS Trust)
Cited by 160
Related Papers
Photodynamic therapy of cancer: An update
|CA A Cancer Journal for Clinicians|2011|5.1k
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Antimicrobial strategies centered around reactive oxygen species – bactericidal antibiotics, photodynamic therapy, and beyond
|FEMS Microbiology Reviews|2013|1.1k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Cell Death Pathways in Photodynamic Therapy of Cancer
|Cancers|2011|675